Short Squeeze Mania.
Citius Pharma (CTXR) Locked and Loaded.
Truly Locked and Loaded. Latest $20 Million Round is Biggest News We've Seen From Citius Pharma (CTXR) Since We've...
Adding Hapbee Tech (HAPB, HAPBF) $0.34 to Biotech Six Pack Watch List.
UPDATE ON BIOTECH SIX PACK, SIX STOCKS WE EXPECT TO DOUBLE.
While the Biotech Stock Review was launched in 2002, the "Biotech 6-Pack, 6 Stocks...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals,...
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial halt for Mino-Lok® (a rare but potential...
Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...
Completion of Enrollment Remains on Track for Q1, 2024
"While we recently had fireworks, we could be looking at real fireworks in the coming year....
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021 @$1.80Cash has Risen From $3.3 Million...
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
INSIDER HOLDINGS
POWERPOINT
LIVE CHART
Adding Citius (CTXR) $0.55 to Watch List.
Citius News Archive
MARKET BEAT
TIP RANKS
Disclaimer. Citius Pharma is a client, please see reports for disclosure and...
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech Six Pack' list. The first addition...
Ouch…Omniq (OMQS).
We had fun with this for a good year, doubling after we found it.
Adding OmniQ (OMQS) $5.00 to the Watch List.
LIVE QUOTE
Then it...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Citius announced that the DMC interim safety and...
Latest article
Adding BCM Resources Corporation (B.V) $0.27, Up 42%, to Watch List.
'Elephant Hunter' Dr. Sergei Diakov is Expanding Drill Footprint, to Outline a Potentially Massive Copper-Gold System Beneath the Surface.
Led by legendary geologist Dr. Sergei...
New Report on Sekur Private Data (SWISF). Palantir’s Open Secure AI.
Palantir CEO Alex Karp discusses open-weight artificial intelligence models, how he believes the technology should be regulated and why the U.S. should avoid Europe’s...
Replimune (REPL) Jumps 100%.
A Nifty $415 Million Gain (in an hour) for Shareholders.
Not out of the woods yet..
Short and to the point: We listened to whole meeting...
